Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$37.38 +4.2%	$25.85	$16.50 ▼ $37.95	$3.26B	N/A	12,757 shs	25,208 shs
ANAB AnaptysBio	$23.17 -0.9%	$21.29	$12.21 ▼ $41.31	$680.73M	-0.26	635,836 shs	454,361 shs
IBRX ImmunityBio	$2.87 +1.1%	$2.67	$1.83 ▼ $7.63	$2.53B	0.14	6.06 million shs	9.12 million shs
MLTX MoonLake Immunotherapeutics	$43.50	$40.88	$31.42 ▼ $58.26	$2.78B	1.23	382,410 shs	240,424 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	+18.63%	+46.24%	+99.89%	+3,737,999,900.00%
ANAB AnaptysBio	0.00%	-0.64%	+11.72%	+35.66%	+1.22%
IBRX ImmunityBio	0.00%	-6.51%	+7.09%	+5.90%	-53.93%
MLTX MoonLake Immunotherapeutics	0.00%	-1.61%	+12.96%	+8.42%	+10.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	2.0801 of 5 stars	3.4	0.0	0.0	0.0	3.7	1.7	0.6
IBRX ImmunityBio	1.9186 of 5 stars	3.6	2.0	0.0	0.0	0.6	1.7	0.6
MLTX MoonLake Immunotherapeutics	1.2245 of 5 stars	3.5	0.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	82.89% Upside
IBRX ImmunityBio	3.20	Buy	$12.25	326.83% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	80.95% Upside

Current Analyst Ratings Breakdown

Latest ANAB, AAPG, IBRX, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	24.24	N/A	N/A	$0.48 per share	77.88
ANAB AnaptysBio	$91.28M	7.46	N/A	N/A	$2.33 per share	9.94
IBRX ImmunityBio	$14.74M	171.85	N/A	N/A	($0.57) per share	-5.04
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)

Latest ANAB, AAPG, IBRX, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
ANAB AnaptysBio	N/A	8.25	8.25
IBRX ImmunityBio	N/A	2.22	2.05
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	N/A
IBRX ImmunityBio	8.58%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	33.50%
IBRX ImmunityBio	76.79%
MLTX MoonLake Immunotherapeutics	12.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable

ANAB, AAPG, IBRX, and MLTX Headlines

Recent News About These Companies

MoonLake Immunotherapeutics (NASDAQ:MLTX) vs. DURECT (NASDAQ:DRRX) Head to Head Survey

June 15, 2025 | americanbankingnews.com

Cantor Fitzgerald Weighs in on MLTX FY2026 Earnings

June 12, 2025 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc.

June 11, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Buy" by Analysts

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts MLTX FY2026 Earnings

June 10, 2025 | marketbeat.com

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News

June 9, 2025 | gurufocus.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 3.9% - What's Next?

June 6, 2025 | marketbeat.com

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help

June 5, 2025 | statnews.com

MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX

June 5, 2025 | nasdaq.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Volume Increase - Here's Why

June 4, 2025 | marketbeat.com

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

June 4, 2025 | zacks.com

Wellington Management Group LLP Lowers Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX)

June 4, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

June 4, 2025 | marketbeat.com

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

June 3, 2025 | seekingalpha.com

Constellation and Meta, Merck, Snowflake: Trending Tickers

June 3, 2025 | finance.yahoo.com

Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT

June 3, 2025 | fiercebiotech.com

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover

June 3, 2025 | msn.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up - Here's What Happened

June 3, 2025 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Outperform Rating from Royal Bank of Canada

June 3, 2025 | marketbeat.com

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

June 3, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB, AAPG, IBRX, and MLTX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$37.38 +1.50 (+4.18%)

As of 06/20/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

AnaptysBio NASDAQ:ANAB

$23.17 -0.22 (-0.94%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.16 -0.01 (-0.02%)

As of 06/20/2025 06:07 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ImmunityBio NASDAQ:IBRX

$2.87 +0.03 (+1.06%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.01 (+0.52%)

As of 06/20/2025 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$43.50 0.00 (0.00%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$43.52 +0.02 (+0.05%)

As of 06/20/2025 07:25 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time